DNA Immunotherapy Shows Durable Response in Advanced Melanoma with Phil L’Huillier Scancell TRANSCRIPT
Download PDFOct 30, 2025
Phil L'Huillier, CEO of Scancell, has developed an off-the-shelf DNA immunotherapy designed to generate a potent and durable immune response against advanced melanoma in patients who are unresponsive to current therapies. Their lead candidate showed significant benefit when added to standard of care...
Oct 30, 2025
Phil L'Huillier, CEO of Scancell, has developed an off-the-shelf DNA immunotherapy designed to generate a potent and durable immune response against advanced melanoma in patients who are unresponsive to current therapies. Their lead candidate showed significant benefit when added to standard of care...
Treating Autoimmune-Driven Dry Eye Disease with Immune Modulator with Elizabeth Jeffords Iolyx TRANSCRIPT
Download PDFSep 12, 2025
Elizabeth Jeffords, CEO and President of Iolyx Therapeutics, discusses dry eye disease and its connection to autoimmune conditions. The company's novel therapeutic topical immune modulator is designed to treat the root inflammation in the eye, which systemic drugs often fail to reach due to the blood-retina barrier....
Sep 12, 2025
Elizabeth Jeffords, CEO and President of Iolyx Therapeutics, discusses dry eye disease and its connection to autoimmune conditions. The company's novel therapeutic topical immune modulator is designed to treat the root inflammation in the eye, which systemic drugs often fail to reach due to the blood-retina barrier....
Nanoparticle Immunotherapy Reducing Cancer Recurrence Extending Survival Rates with Dr. Frank Bedu-Addo PDS Biotechnology TRANSCRIPT
Download PDFAug 25, 2025
Dr. Frank Bedu-Addo, President and CEO of PDS Biotechnology, focuses on the challenge of cancer recurrence and the development of a targeted immunotherapy approach using nanoparticle technology. Their lead immunotherapy candidate is designed to train the immune system to detect and attack microscopic or undetectable...